Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + trametinib with concurrent palliative radiotherapy for BRAF-mutant metastatic melanoma
ACTRN12615000292572Phase 2Terminated
- Sponsor
- Melanoma and Skin Cancer Trials
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in melanoma, sponsored by Melanoma and Skin Cancer Trials. Primary endpoint: Toxicity profile of dabrafenib and trametinib with radiotherapy. Started Jun 2016; status: terminated.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12615000292572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000292572.